Bioinformatics company Golden Helix received a $2.2 million NIH Phase II SBIR grant to advance its VSPGx pharmacogenomics interpretation software. The platform analyzes next-generation sequencing data to predict drug responses and guide clinical care. Planned enhancements include expanded FDA-approved pharmacogenomic data curation, whole-genome sequencing algorithm integration, workflow automation, data warehousing, and support for electronic health record systems to enable real-time alerts and updates.